2013


To access this material please log in or register

Register Authorize
2013/№1

Controversial aspects of myocarditis treatment

Moiseeva O. М.
Federal State Budgetary Institution, “North-West Federal Medical Research Center” of the RF Ministry of Health Care, Akkuratova 2, St.-Petersburg 197341

Keywords: treatment, myocarditis

DOI: 10.18087/rhj.2013.1.1520

The review provides analysis of possibilities of various methods of myocarditis therapy, taking into account main principles of HF patient management, according to which therapy must prevent development of and eliminate the symptoms, slow down disease progression, improve quality of life and disease prognosis.
  1. D'Ambrosio A, Patti G, Manzoli A et al. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart. 2001;85 (5):499–504.
  2. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;1 (57):3–62.
  3. Палеев Н. Р., Одинокова В. А., Гуревич М. А., Найштут Г. М. Миокардиты. – М.: Медицина, 1982. – 272с.
  4. Woodruff JF. Viral myocarditis. A review. Am J Pathol. 1980;101 (2):425–484.
  5. Godsel LM, Leon JS, Engman DM. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in experimental myocarditis. Curr Pharm Des. 2003;9 (9):723–735.
  6. Bahk TJ, Daniels MD, Leon JS et al. Comparison of angiotensin converting enzyme inhibition and angiotensin II receptor blockade for the prevention of experimental autoimmune myocarditis. Int J Cardiol. 2008;125 (1):85–93.
  7. Jankowska EA, Ponikowski P, Piepoli MF et al. Autonomic imbalance and immune activation in chronic heart failure – Pathophysiological links. Cardiovasc Res 2006;70 (3):434–445.
  8. Liu H, Li W, Gu W et al. Immunoregulatory effects of carvedilol on rat experimental autoimmune myocarditis. Scand J Immunol. 2010;71 (1):38–44.
  9. Matsumori A, Igata H, Ono K et al. High doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: a possible mechanism of digitalis toxicity. Jpn Circ J. 1999;63 (12):934–940.
  10. Okura Y, Dec GW, Hare JM et al. A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol. 2003;41 (2):322–329.
  11. Dung NM, Kneen R, Kiem N et al. Treatment of severe diphtheritic myocarditis by temporary insertion of a cardiac pacemaker. Clin Infect Dis. 2002;35 (11):1425–1429.
  12. Fish AE, Pride YB, Pinto DS. Lyme Carditis. Infect Dis Clin N Am 2008;22 (2):275–288.
  13. Zipes DP, Camm AJ, Borggrefe M et al. ACC / AHA / ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation. 2006;114 (10):e385–484.
  14. Nieminen MS, Bohm M, Cowie MR et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26 (4):384–416.
  15. de March Ronsoni R, Feijó RV Jr, Melo LH et al. The use of Levosimendan for myocardiopathy due to acute Chagas' disease. Int J Cardiol. 2009;136 (2):233–235.
  16. Latva-Hirvela J, Kyto V, Saraste A et al. Development of troponin autoantibodies in experimental coxsackievirus B3 myocarditis. Eur J Clin Invest. 2009;39 (6):457–462.
  17. Dickstein K., Vardas P. E., Auricchio A et al. 2010 focused update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur J Heart Fail. 2010;12 (11):1143–1153.
  18. Simon MA, Kormos RL, Murali S et al. Myocardial recovery using ventricular assist devices. Circulation. 2005;112 (9 Suppl): I32‑I36.
  19. Schuerer DJ, Kolovos NS, Boyd KV, Coopersmith CM. Extracorporeal membrane oxygenation: current clinical practice, coding, and reimbursement. Chest 2008;134 (1):179–184.
  20. Chen YS, Yu HY. Choice of mechanical support for fulminant myocarditis: ECMO vs. VAD? Eur J Cardiothorac Surg. 2005;27 (5):931–932.
  21. Moloney ED, Egan JJ, Kelly P et al. Transplantation for myocarditis: a controversy revisited. J Heart Lung Transplant. 2005;24 (8):1103–1110.
  22. Myocarditis: Current Treatment. Overview. (Section 16). Journal of Cardiac Failure 2006;12 (1):e120‑e122.
  23. Палеев Н. Р., Гуревич М. А. Некоронарогенные заболевания миокарда. Состояние проблемы. Клин. мед. 1998;76 (9):4–8.
  24. Meune C, Spaulding C, Mahé I et al.Risks versus benefits of NSAIDs including aspirin in myocarditis: a review of the evidence from animal studies. Drug Saf. 2003;26 (13):975–981.
  25. Bleumink GS, Feenstra J, Sturkenboom MC, Stricker BH. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs. 2003;63 (6):525–534.
  26. Палеев Ф. Н. Миокардиты. Медицинская помощь. 2002;6:3–9.
  27. Keating RJ, Bhatia S, Amin S et al. Hydroxychloroquine-induced cardiotoxicity in a 39‑year-old woman with systemic lupus erythematosus and systolic dysfunction. J Am Soc Echocardiogr. 2005;18 (9):981.
  28. Latham RD, Mulrow JP, Virmani R et al. Recently diagnosed idiopathic dilated cardiomyopathy: incidence of myocarditis and efficacy of prednisone therapy. Am Heart J. 1989;117 (4):876–882.
  29. Parrillo JE, Cunnion RE, Epstein SE et al. A prospective, rando­mized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 1989;321 (16):1061–1068.
  30. Mason JW, O'Connell JB, Herskowitz A et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med. 1995;333 (5):269–275.
  31. Gard A, Shiau J, Guyatt G. The ineffectiveness of immunosuppressive therapy in lymphocytic myocarditis: an overview. Ann Intern Med 1998;129 (4):317–322.
  32. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation. 2001;104 (1):39–45.
  33. Frustaci A, Chimenti C, Calabrese F et al. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation. 2003;107 (6):857–863.
  34. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J. 2009;30 (16):1995–2002.
  35. Cooper LT Jr, Berry GJ, Shabetai R Idiopathic giant-cell myocarditis-natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators.N Engl J Med. 1997;336 (26):1860–1866.
  36. Cooper LT. Jr, Hare JM, Tazelaar HD et al. Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol. 2008;102 (11):1535–1539.
  37. Sabatine MS, Poh KK, Mega JL. et al. Case records of the Massachusetts General Hospital. Case 36–2007. A 31‑year-old woman with rash, fever, and hypotension. N Engl J Med. 2007;357 (21):2167–2178.
  38. Kim JS, Judson MA, Donnino R et al. Cardiac sarcoidosis. Am Heart J. 2009;157 (1):9–21.
  39. Dennert R, Crijns HJ, Heymans S. Acute viral myocarditis. Eur Heart J. 2008;29 (17):2073–2082.
  40. Полетаев А. Б. Физиологическая иммунология (естественные аутоантитела и проблемы наномедицины). – М.: «МИКЛОШ», 2010. – 218с.
  41. Staudt A, Bohm M, Knebel F et al. Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy. Circulation. 2002;106 (19): 2448–2453.
  42. Nussinovitch U, Shoenfeld Y. Intravenous immunoglobulin. Indications and mechanisms in cardiovascular diseases Autoimmun Rev. 2008;7 (6):445–452.
  43. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345 (10):747–755.
  44. McNamara DM, Rosenblum WD, Janosko KM et al. Intravenous immune globulin in the therapy of myocarditis and acute cardio­myo­pathy. Circulation 1997;95 (11):2476–2478.
  45. Goland S, Czer LSC, Siegel RJ et al. Intravenous immunoglobulin treatment for acute fulminant inflammatory cardiomyopathy: Series of six patients and review of literature. Can J Cardiol 2008;24 (7):571–574.
  46. Gullestad L, Aass H, Fjeld JG et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001;103 (2):220–225.
  47. McNamara DM, Holubkov R, Starling RC et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyo­pathy. Circulation. 2001;103 (18):2254–2259.
  48. Yajima T, Knowlton KU. Viral myocarditis: from the perspective of the virus. Circulation. 2009;119 (19):2615–2624.
  49. Matsumori A, Tomioka N, Kawai C. Protective effect of recombinant alpha interferon on coxsackievirus B3 myocarditis in mice. Am Heart J. 1988;115 (6):1229–1232.
  50. Li L, Sherry B. IFN-α expression and antiviral effects are subtype- and cell type-specific in the cardiac response to viral infection. Virology. 2010;396 (1):59–68.
  51. Miric M, Vasiljevic J, Bojic M et al. Long-term follow up of patients with dilated heart muscle disease treated with human leucocytic interferon alpha or thymic hormones initial results. Heart. 1996;75 (6):596–601.
  52. Nishio K, Konndo T, Okada S et al. Pericarditis and chronic inflammatory demyelinating polyneuropathy during therapy with pegylated interferon alfa-2a for chronic hepatitis C. World J Hepatol. 2010;2 (9):358–361.
  53. Kuhl U, Pauschinger M, Schwimmbeck PL et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation. 2003;107 (22):2793–2798.
  54. Zimmermann O, Rodewald C, Radermacher M et al. Interferon beta-1b therapy in chronic viral dilated cardiomyopathy-is there a role for specific therapy? J Card Fail. 2010;16 (4):348–356.
  55. Kuhl U, Pauschinger M, Noutsias M et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with ‘‘idiopathic’’ left ventricular dysfunction. Circulation. 2005;111 (7):887–893.
  56. Kindermann I, Kindermann M, Kandolf R et al. Predictors of outcome in patients with suspected myocarditis. Circulation. 2008;118 (6):639–648.
  57. Henke A, Jarasch N, Wutzler P. Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis. Expert Rev Vaccines. 2008;7 (10):1557–1567.
  58. Schultz JC, Hilliard AA, Cooper LT, Rihal CS. Diagnosis and treatment of viral myocarditis. Mayo Clin Proc. 2009;84 (11):1001–1009.
Moiseeva O. М. Controversial aspects of myocarditis treatment. Russian Heart Journal. 2013;12(1):57-64

To access this material please log in or register

Register Authorize
Ru En